>
Rex Bionics logo

RXB - Rex Bionics Share Price

1.75p 0.0  0.0%

Last Trade - 26/05/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £463k
Position in Universe th / 1828
Bullish
Bearish
Unlock RXB Revenue
Momentum
Relative Strength (%)
1m -69.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
0.10 0.000 0.000 0.000 0.18 0.45 1.00 2.00 +35.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2016, RexBionics PLC revenues increased 7% to £196K. Net lossincreased 21% to £2.6M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsAdministrative Expenses increase of 22% to £3M (expense),Finance credit decrease from £113K (income) to £0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RXB Revenue Unlock RXB Revenue

Net Income

RXB Net Income Unlock RXB Revenue

Normalised EPS

RXB Normalised EPS Unlock RXB Revenue

PE Ratio Range

RXB PE Ratio Range Unlock RXB Revenue

Dividend Yield Range

RXB Dividend Yield Range Unlock RXB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RXB EPS Forecasts Unlock RXB Revenue
Profile Summary

Rex Bionics Plc is engaged in the research and development, manufacture and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.

Directors
Last Annual March 31st, 2016
Last Interim September 30th, 2016
Incorporated November 13, 2007
No. of Shareholders: n/a
No. of Employees: 2
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange London Stock Exchange
Shares in Issue 39,803,219
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RXB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RXB
Upcoming Events for RXB
Frequently Asked Questions for Rex Bionics
What is the Rex Bionics share price?

As of 26/05/17, shares in Rex Bionics are trading at 1.75p, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Rex Bionics share price performed this year?

Shares in Rex Bionics are currently trading at 1.75p and the price has moved by -95.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rex Bionics price has moved by -96.14% over the past year.

What are the analyst and broker recommendations for Rex Bionics?

Of the analysts with advisory recommendations for Rex Bionics, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Rex Bionics is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Rex Bionics next release its financial results?

Rex Bionics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2017-09-30
What is the Rex Bionics dividend yield?

Rex Bionics does not currently pay a dividend.

Does Rex Bionics pay a dividend?

Rex Bionics does not currently pay a dividend.

When does Rex Bionics next pay dividends?

Rex Bionics does not currently pay a dividend.

How do I buy Rex Bionics shares?

To buy shares in Rex Bionics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rex Bionics?

Shares in Rex Bionics are currently trading at 1.75p, giving the company a market capitalisation of £n/a.

Where are Rex Bionics shares listed? Where are Rex Bionics shares listed?

Here are the trading details for Rex Bionics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: RXB
What kind of share is Rex Bionics?

We were not able to load our ranking data for Rex Bionics

Is there a Rex Bionics share price forecast 2021?

We were not able to load any forecast data for Rex Bionics.

How can I tell whether the Rex Bionics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rex Bionics. Over the past six months, the relative strength of its shares against the market has been -92.51%. At the current price of 1.75p, shares in Rex Bionics are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rex Bionics PE Ratio?

We were not able to find PE ratio data for Rex Bionics.

Who are the key directors of Rex Bionics?

Rex Bionics's management team is headed by:

Jeremy Curnock-Cook - VCH
William Hunter - DRC
David Macfarlane - CHM
K. Robinson - SEC
Dominic Simon - CEO
Joseph Cucolo - NED
Who are the major shareholders of Rex Bionics?

Here are the top five shareholders of Rex Bionics based on the size of their shareholding:

Similar to RXB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.